Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes

Author(s): Gerd Ludwig, Marija Mojić, Mirna Bulatović, Sanja Mijatović, Danijela Maksimović-Ivanić, Dirk Steinborn, Goran N. Kaluđerović.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry

Volume 16 , Issue 11 , 2016

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1–4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5–8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1–4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug’s tumoricidal action on 8505C cell line.

Keywords: Apoptosis, autophagy, caspase, cisplatin, iridium(III) complexes, ruthenium(II) complexes.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 11
Year: 2016
Page: [1455 - 1460]
Pages: 6
DOI: 10.2174/1871520615666151029100749
Price: $58

Article Metrics

PDF: 27
HTML: 3
EPUB: 1
PRC: 1